BOUNCE

[cintrix]

IOBT down more in premaket -down bigly yesterday - was up in premarket initially on news that was apparently old so it retreated and then dropped more on company saying they have cash to support operations through the third quarter of 2024. Morgan Stanley analyst Michael Ulz reiterated a Buy rating on IO Biotech (IOBT – Research Report) yesterday and set a price target of $11.00. The company’s shares closed yesterday at $1.61. https://markets.businessinsider.com/news/stocks/morgan-stanley-sticks-to-its-buy-rating-for-io-biotech-iobt-1032390255#:~:text=Morgan%20Stanley%20analyst%20Michael%20Ulz,IVERIC%20bio%2C%20and%20Ionis%20Pharmaceuticals